Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March

Exelixis, Inc. (Nasdaq: EXEL) has announced its participation in a series of fireside chats at prominent investor conferences throughout March. These presentations, aimed at driving investor engagement and showcasing the company's innovative oncology solutions, will be webcasted for wider accessibility. Interested investors and stakeholders can tune in to the conferences via Exelixis's official website at www.exelixis.com under the Investors & News section.

The schedule for the events includes the TD Cowen 46th Annual Health Care Conference on March 3 at 1:10 p.m. ET, followed by the Leerink Partners 2026 Global Healthcare Conference, where Exelixis will present on March 10 at 10:40 a.m. ET. Additionally, the company is slated to participate in the 2026 Citizens Life Sciences Conference and the Barclays 28th Annual Global Healthcare Conference, both taking place in Miami on March 11, with presentation times of 9:35 a.m. ET and 12:00 p.m. ET, respectively.

Exelixis is recognized for its commitment to oncology, innovating next-generation medicines targeted at various tumor types. The company’s focus lies in developing a robust pipeline of small molecules and biotherapeutics, with notable products like CABOMETYX® (cabozantinib) and the novel oral kinase inhibitor zanzalintinib. Exelixis’s mission is to deliver transformational treatments that provide hope and improve outcomes for cancer patients.

Replays of the live webcasts will be available for at least 30 days following each conference, ensuring that interested parties have ample opportunity to engage with the content. For further inquiries, investors can reach Varant Shirvanian, Director of Investor Relations, at Exelixis.

Exelixis, Inc. (Nasdaq: EXEL) is positioning itself strategically in the oncology market, and the upcoming series of fireside chats at key investor conferences in March will provide a valuable platform to outline its vision and pipeline potential. Investors should consider closely monitoring these presentations as Exelixis continues to enhance its portfolio of cancer therapies and showcases its commitment to advancing innovative treatments.

Scheduled to participate in four notable conferences, each with a robust agenda—TD Cowen, Leerink Partners, and Barclays—Exelixis will offer insights into its cutting-edge advancements such as the oral kinase inhibitor, zanzalintinib, alongside its flagship CABOMETYX® (cabozantinib). Each presentation presents an opportunity for management to articulate long-term strategies, discuss recent data, and engage with investors regarding the implications of their ongoing research initiatives.

For investors, these events are crucial not only for understanding Exelixis' current performance but also for gaining insight into future growth trajectories. Given Exelixis’ history of robust pipeline development, including targeting a broader range of tumor types, the discourse during the sessions may also highlight potential collaborations or partnerships that could drive further innovation.

With the healthcare landscape evolving rapidly, investors should evaluate how Exelixis fits into broader market trends in oncology. The investments in R&D that Exelixis has made signal a drive for competitive advantage in a space flooded with both opportunity and patent expirations. As a proactive measure, investors are encouraged to log into the Exelixis website to access the webcasts and replays, ensuring they stay informed about the company's strategic direction.

In summary, as Exelixis hosts these pivotal discussions, potential and existing investors should consider the evolving landscape and implications for investment strategy, positioning themselves for future gains stemming from Exelixis' innovations in cancer care.